FREE TREATMENT REPORT

See ratings and reviews when you sign up for an account.

Megavoltage CT (MVCT) Imaging for Intracavitary Radiation Treatment in Cervix Cancer

This study is currently Recruiting

April 2007 By Alberta Health Services

First Recieved on July 26, 2005

Last Updated on September 22, 2008

Sponsor: Alberta Health Services
Collaborators:
Information provided by: Alberta Health Services
Identifier: NCT00124423

Purpose

The Cross Cancer Institute has recently acquired a tomotherapy radiotherapy treatment machine; the first of its kind in Canada. It has the potential to improve cancer treatment outcomes where radiotherapy is used. Cervix cancer is a disease where radiotherapy is a particularly important treatment modality. The researchers believe that by combining tomotherapy (which has the ability to give higher doses of radiation to areas of cancer while sparing normal tissues) with radiotherapy given from inside the uterus and vagina (brachytherapy) disease outcomes will be improved. For this to be possible the researchers will need to accurately map the doses of radiation given to the cervix, uterus and other pelvic organs from these two types of radiation treatment. As well as being used for treatment, the tomotherapy machine can also be used for taking medical images by using very much lower doses of radiation. This study will allow the researchers to develop the mapping process by using very low doses of radiation on the tomotherapy unit to take medical x-ray images of patients being treated by brachytherapy for cervix cancer. In this special circumstance the researchers expect the images to be of a higher quality than for conventional computed tomography (CT) scanning or magnetic resonance imaging (MRI) scanning.

Study Type: Observational
Study Design: Time Perspective: Prospective

Eligibility

Ages Eligible for Study:N/A
Genders Eligible for Study:Female
Accepts Healthy Volunteers:No
Criteria

Inclusion Criteria: - Patients undergoing brachytherapy for cervix cancer Exclusion Criteria: - Patient refusal

Investigators

  • Investigator: Robert Pearcey, MD - Principal Investigator - Alberta Health Services

Locations

  • Cross Cancer Institute

    Edmonton, Alberta T6G 1Z2 Canada

advertisement
V2012.311.925.327
Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.